RayzeBio

Boerner

Pharma

BMS' dealmaking appetite remains intact, CEO says

As other pharmas pump the brakes on big M&A, Bristol Myers Squibb says it still has dealmaking cash ready to deploy if the right target comes along.

Fraiser Kansteiner Jun 12, 2024 10:55am

radiotherapy radiopharmaceuticals

Supply constraints force pause of BMS, RayzeBio trial enrollment

Jun 3, 2024 3:38pm

BMS

JPM24: BMS CEO Boerner focuses on pipeline—even after M&A deals

Jan 8, 2024 2:06pm